Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-κB/cyclooxygenase-2 signaling pathway

Clinical Cancer Research

Volumn 11, Issue 16, 2005, Pages 5809-5820

  Lin, Ming Tsain ^a   Zuon, Chung Yaou ^b   Chang, Cheng Chi ^b   Chen, Szu Ta ^a   Chen, Chih Ping ^d   Lin, Been Ren ^a   Wang, Ming Yang ^a   Jeng, Yung Ming ^a   Chang, King Jen ^a,c   Lee, Po Huang ^a   Chen, Wei Jao ^a   Kuo, Min Liang ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d TAO YUAN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; CYCLOOXYGENASE 2; CYSTEINE RICH PROTEIN 61; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; LIPOSOME; MESSENGER RNA; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BOYDEN CHAMBER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CELL MOTILITY; CELL STRAIN AGS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; EXPRESSION VECTOR; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCUBATOR; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOGENESIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNOHISTOCHEMISTRY; INTEGRINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NF-KAPPA B; PLASMIDS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRANSFECTION;

EID: 23844524758     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2639     Document Type: Article

References (68)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:535-62.
2. Gunderson LL, Donohue JH, Burch PA, et al. Clinical oncology. 2nd ed. New York (NY): Churchill Livingstone; 2000. p. 1545-79.
3. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42.
4. Thun MJ. NSAID use and decreased risk of gastrointestinal cancers. GastOroenterol Clin North Am 1996;25:333-48.
5. Thun MJ, Namboodiri MM, Calle EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
6. Ristimäki A, Honkanen N, Jänkälä H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997;57:1276-80.
7. Uefuji K, Ichikura T, Mochizuki H. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001;76:26-30.
8. Han SL,Tang HJ, Hua YW, et al. Expression of COX-2 in stomach cancers and its relation to their biological features. Dig Surg 2003;20:107-14.
9. Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001;91:1876-81.
10. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 over expression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451-5.
11. Xue YW, Zhang QF, Zhu ZB, et al. Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma. World J Gastroenterol 2003;9:250-3.
12. Tatsuguchi A, Matsui K, Shinji Y et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 2004;35:488-95.
13. Leung WK, To KF, Go MY, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 2003;23:1317-22.
14. 1 transition of cultured mouse cells. EMBO J 1985;4:3145-51.
15. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004;363:62-4.
16. Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003;3:15.
17. Brigstock DR. The connective tissue growth factor/cysteine-rich 61/nephroblastoma over expressed (CCN) family. Endocr Rev 1999;20:189-206.
18. Abreu JG, Ketpura NI, Reversade B, et al. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat Cell Biol 2002;4:599-604.
19. Grzeszkiewicz TM, Lindner V, Chen N, et al. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin α(6)β(1) and cell surface heparin sulfate proteoglycans. Endocrinology 2002;143:1441-50.
20. Babic AM, Kireeva ML, Kolesnikova TV, et al. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998;95:6355-60.
21. Lin MT, Chang CC, Chen ST, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-κB-dependent XIAP up-regulation. J Biol Chem 2004;279:24015-23.
22. Tsai MS, Bogart DF, Castaneda JM, et al. Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 2002;21:8178-85.
23. Xie D, Yin D, Tong X, et al. Cyr61 is over expressed in gliomas and involved in integrin-linked kinase-mediated Akt and β-catenin-TCF/Lef signaling pathways. Cancer Res 2004;64:1987-96.
24. Menendez JA, Mehmi I, Griggs DW, et al. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003;10:141-52.
25. Tsai MS, Bogart DF, Li P, et al. Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene 2002;21:964-73.
26. Pilarsky CP, Schmidt U, Eissrich C, et al. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998;36:85-91.
27. Sampath O, Zhu Y, Winneker RC, et al. Aberrant expression of Cyr61, a member of the CCN (CTGF/Cyr61/Cef10/NOVH) family, and dysregulation by 17 β-estradiol and basic fibroblast growth factor in human uterine leiomyomas. J Clin Endocrinol Metab 2001;86:1707-15.
28. Croci S, Landuzzi L, Astolfi A, et al. Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res 2004;64:1730-6.
29. Tong X, Xie D, O'Kelly J, et al. Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. J Biol Chem 2001;276:47709-14.
30. Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 2002;5:153-65.
31. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31:2-11.
32. Uefuji K, Ichikura T, Mochizuki H. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000;6:135-8.
33. Smartt HJ, Elder DJ, Hicks DJ, et al. Increased NF-κB DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cells. Br J Cancer 2003;89:1358-65.
34. Jung YJ, Isaacs JS, Lee S, et al. IL-1β-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17:2115-7.
35. Liu W, Reinmuth N, Stoeltzing O, et al. Cyclooxygenase-2 is up-regulated by interleukin-1 β in human colorectal cancer cells via multiple signaling pathways. Cancer Res 2003;63:3632-6.
36. Charalambous MP, Maihofner C, Bhambra U, et al. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-κB and IκB kinase-α in human colorectal cancer epithelial cells. Br J Cancer 2003;88:1598-604.
37. Maihofner C, Charalambous MP, Bhambra U, et al. Expression of cyclooxygenase-2 parallels expression of interleukin-1β interleukin-6 and NF-κB in human colorectal cancer. Carcinogenesis 2003;24:665-71.
38. Lim JW, Kim H, Kim KH. Nuclear factor-κB regulates cyclooxygenase-2 expression and cell proliferation in human gastric cancer cells. Lab Invest 2001;81:349-60.
39. Chen N, Leu SJ, Todorovic V, et al. Identification of a novel integrin α vβ 3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J Biol Chem 2004 Aug 10.
40. Leu SJ, Liu Y, Chen N, et al. Identification of a novel integrin α 6 β 1 binding site in the angiogenic inducer CCN1 (CYR61). J Biol Chem 2003;278:33801-8.
41. Leu SJ, Lam SC, Lau LF. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins αvβ3 and α6β1 in human umbilical vein endothelial cells. J Biol Chem 2002;277:46248-55.
42. Schober JM, Chen N, Grzeszkiewicz TM, et al. Identification of integrin α(M)β(2) as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood 2002;99:4457-65.
43. Tsai MS, Hornby AE, Lakins J, et al. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000;60:5603-7.
44. Tong X, O'Kelly J, Xie D, et al. Cyr61 suppresses the growth of non-small-cell lung cancer cells via the β-catenin-c-myc-p53 pathway. Oncogene 2004;23:4847-55.
45. Xie D, Nakachi K, Wang H, et al. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001;61:8917-23.
46. Sampath D, Winneker RC, Zhang Z. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17β-estradiol and over expression in human breast cancer. Endocrinology 2001;142:2540-8.
47. Pilarsky CP, Schmidt U, Eissrich C, et al. Expression of the extracellular matrix signaling molecule Cyr61 is downregulated in prostate cancer. Prostate 1998;36:85-91.
48. Xie D, Yin D, Wang HJ, et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004;10:2072-81.
49. Fu SL, Wu YL, Zhang YP, et al. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol 2004;10:1971-4.
50. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 over expression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999;94:451-5.
51. Yu HG, Li JY Yang YN, et al. Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer. Cancer Lett 2003;195:43-51.
52. Leung WK, To KF, Ng YP, et al. Association between cyclo-oxygenase-2 over expression and missense p53 mutations in gastric cancer. Br J Cancer 2001;84:335-9.
53. Lim HY, Joo HJ, Choi JH, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6:519-25.
54. 2-terminal kinase. Gastroenterology 2004;126:136-47.
55. Wong BC, Jiang X, Fan XM, et al. Suppression of RelA/p65 nuclear translocation independent of IκB-α degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 2003;22:1189-97.
56. Hu PJ, Yu J, Zeng ZR, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195-200,
57. Sugiura T, Saikawa Y, Kubota T, et al. Combination chemotherapy with JTE-522, a novel selective cyclooxygenase-2 inhibitor, and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo 2003;17:229-33.
58. van Rees BP, Sivula A, Thoren S, et al. Expression of microsomal prostaglandin E synthase-1 in intestinal type gastric adenocarcinoma and in gastric cancer cell lines. Int J Cancer 2003;107:551-6.
59. Ehrhardt H, Fulda S, Schmid I, et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 2003;22:3842-52.
60. Arlt A, Vorndamm J, Muerkoster S, et al. Autocrine production of interleukin 1β confers constitutive nuclear factor κB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002;62:910-6.
61. Greten FR, Eckmann L, Greten TF, et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96.
62. Ducut Sigala JL, Bottero V, Young DB, et al. Activation of transcription factor NF-κB requires ELKS, an IκB kinase regulatory subunit. Science 2004;304:1963-7.
63. Xiong HQ, Abbruzzese JL, Lin E, et al. NF-κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 2004;108:181-8.
64. Karashima T, Sweeney P, Kamat A, et al. Nuclear factor-κB mediates angiogenesis and metastasis of human bladder cancer through the regulation of interleukin-8. Clin Cancer Res 2003;9:2786-97.
65. Huber MA, Azoitei N, Baumann B, et al. NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114:569-81.
66. Ougolkov A, Zhang B, Yamashita K, et al. Associations among β-TrCP, an E3 ubiquitin ligase receptor, β-catenin, and NF-κB in colorectal cancer. J Natl Cancer Inst 2004;96:1161-70.
67. Sasaki N, Morisaki T, Hashizume K, et al. Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001;7:4136-42.
68. Nie M, Pang L, Inoue H, et al. Transcriptional regulation of cyclooxygenase 2 by bradykinin and interleukin-1β in human airway smooth muscle cells: involvement of different promoter elements, transcription factors, and histone h4 acetylation. Mol Cell Biol 2003;23:9233-44.